H2020-JTI-IMI2-2015-07-two-stage
H2020-JTI-IMI2-2015-07-two-stage
- Programme
- H2020
- Funded projects (dataset)
- 7
- EU contribution (sum)
- €46,794,801
- Portal deadline
- —
Leading topic in historical projects: IMI2-2015-07-01
Start here
Suggested partners for this call
Who coordinated consortia under this call, plus a complementary slice (topic leaders, research partners, or frequent non-coordinators). For industry lists, CSV export, and consortium size — open Proposal partner finder.
Top coordinators
Organisations that coordinated the most funded projects under this call.
- AXXAM1 coordinated
- GERMAN CANCER RESEARCH CENTER1 coordinated
- EORTC1 coordinated
- LONDON SCHOOL OF ECONOMICS AND POLITICAL SCIENCE1 coordinated
- UOXF1 coordinated
- UMC UTRECHT1 coordinated
- UKB1 coordinated
Organisations strong on this topic
Broader signal: frequent participants across funded projects tagged with the same topic codes as this call (not limited to coordinators).
- ABBV2 topic projects
- CNRS2 topic projects
- AU1 topic projects
- UNIVERSITAIR MEDISCH CENTRUM GRONINGEN1 topic projects
- ANTAROS MEDICAL AB1 topic projects
- BAYER AKTIENGESELLSCHAFT1 topic projects
- Bayer Pharma AG1 topic projects
- BIOXYDYN LIMITED1 topic projects
- BRUKER BIOSPIN GMBH & CO KG1 topic projects
- BRUKER BIOSPIN MRI GMBH1 topic projects
- CHALMERS TEKNISKA HOGSKOLA AB1 topic projects
- DZNE1 topic projects
Frequent collaborators
Pairs that often appear together in the same funded project under this call.
- BAYER AKTIENGESELLSCHAFT · PFIZER3 shared
DE ↔ UK
- 3 shared
- BAYER AKTIENGESELLSCHAFT · NOVARTIS3 shared
DE ↔ CH
- ROCHE · BAYER AKTIENGESELLSCHAFT3 shared
CH ↔ DE
- ROCHE · ELI LILLY AND COMPANY LTD2 shared
CH ↔ UK
- Novo Nordisk · BAYER AKTIENGESELLSCHAFT2 shared
DK ↔ DE
- Novo Nordisk · PFIZER2 shared
DK ↔ UK
- 2 shared
- JANSSEN PHARMACEUTICA NV · AMGEN2 shared
BE ↔ BE
- JANSSEN PHARMACEUTICA NV · INSERM2 shared
BE ↔ FR
- JANSSEN PHARMACEUTICA NV · NOVARTIS2 shared
BE ↔ CH
- 2 shared
- 2 shared
- 2 shared
- JANSSEN PHARMACEUTICA NV · SARD2 shared
BE ↔ FR
- JANSSEN PHARMACEUTICA NV · ROCHE2 shared
BE ↔ CH
- 2 shared
- JANSSEN PHARMACEUTICA NV · PFIZER2 shared
BE ↔ UK
Proposal partner finder
One page with suggested coordinators, strong and industry partners, topic leaders, typical consortium size, similar projects — plus CSV or print / PDF export for your shortlist.
Typical consortium pattern
Derived from historical funded projects linked to this CORDIS call in Grantibase.
- Avg. orgs / project
- 23.57
- Median orgs / project
- 22
- Min / max orgs
- 6 – 36
Country presence
Participant rows (an org can appear in multiple countries if data varies).
- United Kingdom37
- Germany32
- France23
- Belgium12
- Sweden11
- Switzerland11
- Netherlands11
- Italy6
- Spain5
- Denmark4
- United States4
- Austria3
- Portugal2
- Norway2
- Hungary1
- Greece1
Organization types
- company34 orgs · 57 rows
- university37 orgs · 43 rows
- research_institute29 orgs · 32 rows
- sme13 orgs · 13 rows
- other12 orgs · 12 rows
- public_body8 orgs · 8 rows
Topics in funded projects
- IMI2-2015-07-01IMI2-2015-07-01· 1 projects
- IMI2-2015-07-02IMI2-2015-07-02· 1 projects
- IMI2-2015-07-03IMI2-2015-07-03· 1 projects
- IMI2-2015-07-04IMI2-2015-07-04· 1 projects
- IMI2-2015-07-05IMI2-2015-07-05· 1 projects
- IMI2-2015-07-06IMI2-2015-07-06· 1 projects
- IMI2-2015-07-07IMI2-2015-07-07· 1 projects
Related funded projects
Largest EU contributions in this call — useful to see who already won funding on similar lines.
Open full project list in advanced search
| Project | Programme | EU contribution |
|---|---|---|
| IB4SD-TRISTAN Imaging Biomarkers (IBs) for Safer Drugs: Validation of Translational Imaging Methods in Drug Safety Assessment - Sofia ref.: 116106 | H2020 | €12,000,000 |
| BigData Heart Big Data 4 Better Hearts - Sofia ref.: 116074 | H2020 | €9,664,970 |
| MACUSTAR Develop and validate appropriate and acceptable outcome measures in intermediate age-related macular degeneration for future interventional clinical trials - Sofia ref.: 116076 | H2020 | €8,025,000 |
| ITCC-P4 ITCC Pediatric Preclinical POC Platform – Sofia ref.: 116064 | H2020 | €7,370,000 |
| IMPRiND Inhibiting Misfolded protein PRopagation in Neurodegenerative Diseases - Sofia ref.: 116060 | H2020 | €4,684,998 |
| DO-IT Big Data for Better Outcomes, Policy Innovation and Healthcare System Transformation - Sofia ref.: 116055 | H2020 | €3,549,833 |
| NGN-PET Modelling Neuron-Glia Networks into a drug discovery platform for Pain Efficacious Treatments - Sofia ref.: 116072 | H2020 | €1,500,000 |